BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ali Mohamed H, Ammar YA, A M Elhagali G, A Eyada H, S Aboul-Magd D, Ragab A. In Vitro Antimicrobial Evaluation, Single-Point Resistance Study, and Radiosterilization of Novel Pyrazole Incorporating Thiazol-4-one/Thiophene Derivatives as Dual DNA Gyrase and DHFR Inhibitors against MDR Pathogens. ACS Omega 2022;7:4970-90. [PMID: 35187315 DOI: 10.1021/acsomega.1c05801] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Abdelgalil MM, Ammar YA, Elhag Ali GA, Ali AK, Ragab A. A novel of quinoxaline derivatives tagged with pyrrolidinyl scaffold as a new class of antimicrobial agents: Design, synthesis, antimicrobial activity, and molecular docking simulation. Journal of Molecular Structure 2023;1274:134443. [DOI: 10.1016/j.molstruc.2022.134443] [Reference Citation Analysis]
2 Bhaskaran RP, Sreelekha MK, Babu BP. Metal‐free Synthesis of Trisubstituted Pyrazoles by the Reaction Between Hydrazones and Activated Olefins. ChemistrySelect 2022;7. [DOI: 10.1002/slct.202202773] [Reference Citation Analysis]
3 Hassan AS, Morsy NM, Aboulthana WM, Ragab A. In vitro enzymatic evaluation of some pyrazolo[1,5‐ a ]pyrimidine derivatives: Design, synthesis, antioxidant, anti‐diabetic, anti‐Alzheimer, and anti‐arthritic activities with molecular modeling simulation. Drug Development Research 2022. [DOI: 10.1002/ddr.22008] [Reference Citation Analysis]
4 Ayman R, Radwan AM, Elmetwally AM, Ammar YA, Ragab A. Discovery of novel pyrazole and pyrazolo[1,5‐ a ]pyrimidine derivatives as cyclooxygenase inhibitors (COX‐1 and COX‐2) using molecular modeling simulation. Archiv der Pharmazie 2022. [DOI: 10.1002/ardp.202200395] [Reference Citation Analysis]
5 Ragab A, Abusaif MS, Gohar NA, Aboul-magd DS, Fayed EA, Ammar YA. Development of new spiro[1,3]dithiine-4,11'-indeno[1,2-]quinoxaline derivatives as Sortase A inhibitors and radiosterilization with molecular modeling simulation. Bioorganic Chemistry 2022. [DOI: 10.1016/j.bioorg.2022.106307] [Reference Citation Analysis]
6 Ammar YA, Micky JA, Aboul‐magd DS, Abd El‐hafez SMA, Hessein SA, Ali AM, Ragab A. Development and radiosterilization of new hydrazono‐quinoline hybrids as DNA gyrase and topoisomerase IV inhibitors: Antimicrobial and hemolytic activities against uropathogenic isolates with molecular docking study. Chem Biol Drug Des 2022. [DOI: 10.1111/cbdd.14154] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Ragab A, Abusaif MS, Aboul-Magd DS, Wassel MMS, Elhagali GAM, Ammar YA. A new exploration toward adamantane derivatives as potential anti-MDR agents: Design, synthesis, antimicrobial, and radiosterilization activity as potential topoisomerase IV and DNA gyrase inhibitors. Drug Dev Res 2022. [PMID: 35716118 DOI: 10.1002/ddr.21960] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Saadon KE, Taha NMH, Mahmoud NA, Elhagali GAM, Ragab A. Synthesis, characterization, and in vitro antibacterial activity of some new pyridinone and pyrazole derivatives with some in silico ADME and molecular modeling study. J IRAN CHEM SOC. [DOI: 10.1007/s13738-022-02575-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ragab A, Ammar YA, Ezzat A, Mahmoud AM, Mohamed MBI, El-Tabl AS, Farag RS. Synthesis, characterization, thermal properties, antimicrobial evaluation, ADMET study, and molecular docking simulation of new mono Cu (II) and Zn (II) complexes with 2-oxoindole derivatives. Comput Biol Med 2022;145:105473. [PMID: 35395516 DOI: 10.1016/j.compbiomed.2022.105473] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Eldeeb M, Sanad EF, Ragab A, Ammar YA, Mahmoud K, Ali MM, Hamdy NM. Anticancer Effects with Molecular Docking Confirmation of Newly Synthesized Isatin Sulfonamide Molecular Hybrid Derivatives against Hepatic Cancer Cell Lines. Biomedicines 2022;10:722. [DOI: 10.3390/biomedicines10030722] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]